{"url_path":"/sec/rmtg/10-k/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1760026/0001213900-26-056841-index.html","accession_number":"0001213900-26-056841","cik":"0001760026","ticker":"RMTG","issuer_name":"Regenerative Medical Technology Group Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1760026/0001213900-26-056841-index.html","primary_entity_key":"0001760026","primary_entity_name":"Regenerative Medical Technology Group Inc."},"word_count":674,"has_tables":true,"body_markdown":"**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n** **\n\n**FORM 10-K**\n\n** **\n\n**(Mark One)**\n\n☒ **ANNUAL REPORT PURSUANT TO SECTION 13\nOR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n** **\n\nFor the fiscal year ended December 31, 2025\n\n** **\n\n**OR**\n\n** **\n\n☐ **TRANSITION REPORT PURSUANT TO SECTION\n13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n** **\n\nFor the transition period from             \nto             .\n\n** **\n\nCommission file number: **000-56010**\n\n** **\n\n**Regenerative Medical Technology Group Inc.**\n\n**(Exact name of registrant as specified in its\ncharter)**\n\n** **\n\n**Nevada**   **88-0492191**\n\n(State or other jurisdiction of\n\nincorporation or organization)   (I.R.S. Employer\n\nIdentification No.)\n\n** **\n\n**433 Plaza Real Suite 275**\n\n**Boca Raton, Florida 33432**\n\n(Address of principal executive offices) (Zip Code)\n\n** **\n\n**(800) 956-3935**\n\n(Registrant’s telephone number, including\narea code)\n\n \n\n \n\n(Former name, former address and former fiscal\nyear, if changed since last report)\n\n** **\n\nSecurities registered under Section 12(b) of the\nExchange Act: **None**\n\n** **\n\nSecurities registered under Section 12(g) of the\nExchange Act: **Common Stock, par value $0.001 per share**\n\n** **\n\nIndicate by check mark if the registrant is a\nwell-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐    No ☒\n\n** **\n\nIndicate by check mark if the registrant is not\nrequired to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐   No ☒\n\n** **\n\nIndicate by check mark whether the registrant\n(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months\n(or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements\nfor the past 90 days. Yes ☒   No ☐\n\n** **\n\nIndicate by check mark whether the\nregistrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T\n(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to\nsubmit such files). Yes ☒   No ☐\n\n \n\nIndicate by check mark whether the registrant\nis a large, accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.\nSee the definitions of “large, accelerated filer,” “accelerated filer,” “smaller reporting company,”\nand “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n** **\n\nLarge, accelerated filer ☐ Accelerated filer ☐\n\nNon-accelerated filer ☒ Smaller reporting company ☒\n\n  Emerging growth company ☐\n\n \n\nIf an emerging growth company, indicate by check\nmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant\nhas filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial\nreporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or\nissued its audit report. ☐\n\n \n\nIf securities are registered pursuant to Section\n12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction\nof an error to previously issued financial statements. ☐\n\n \n\nIndicate by check mark whether any of those error\ncorrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive\nofficers during the relevant recovery period pursuant to §240.10D-1(b). ☐\n\n \n\nIndicate by check mark whether the registrant\nis a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\n \n\nState the aggregate market value of the voting\nand non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the\naverage bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second\nfiscal quarter $612,544.\n\n \n\nIndicate the number of shares outstanding of each\nof the registrant’s classes of common stock, as of the latest practicable date: 13,138,968 shares as of May 14, 2026\n\n** **\n\n \n\n** **\n\n \n\n**TABLE OF CONTENTS**\n\n \n\n[**PART I**](#a_001)\n \n1"}